Benjamín Guzmán-González

Mr. Benjamín Guzmán-González

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Joaquín CalatayudJoaquín Calatayud
Joaquín Calatayud
BGBenjamín Guzmán-González
Benjamín Guzmán-González
LALars Louis Andersen
Lars Louis Andersen
Carlos Cruz-MontecinosCarlos Cruz-Montecinos
Carlos Cruz-Montecinos
MMMaría Teresa Morell
María Teresa Morell
Jose Casaña GranellJose Casaña Granell
Jose Casaña Granell
Low back pain (LBP) is the leading cause of disability and one of the most common reasons for physician visits in primary care, with a 33% rate of recurrence during the first year. However, the most optimal exercise program in this context remains unknown. The objective was to evaluate the effectiveness of a group-based progressive strength training program in non-specific chronic LBP (CLBP) patients in primary care on pain recurrence and physical function. Eighty-five patients with non-specific CLBP were separated into two groups (Intervention group: completed a progressive strength training program 3 days per week for 8 weeks; Control group: received the usual care). The intervention group showed a recurrence rate of 8.3%, while the control group had a recurrence rate of 33.3% and a shorter time until the first recurrent episode. The intervention group showed increased lumbar extensor strength, left-hand handgrip strength, and reduced the number of pain sites compared with the control group. Results also showed greater odds for reducing LBP intensity and disability in the intervention group. In conclusion, a group-based progressive strength training program is a more effective and efficient alternative than Back-School programs and can easily be carried out in the primary health care context.

3 April 2020 in European Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
BGBenjamín Guzmán-González
Benjamín Guzmán-González
CBClaudio Bustos-Briones
Claudio Bustos-Briones
Joaquín CalatayudJoaquín Calatayud
Joaquín Calatayud
CTClaudio Tapia
Claudio Tapia
JTJulio Torres-Elgueta
Julio Torres-Elgueta
Carlos Cruz-MontecinosCarlos Cruz-Montecinos
Carlos Cruz-Montecinos

1 May 2020 in Haemophilia
Verified
Journal Article
Closed access
PDF file
Carlos Cruz-MontecinosCarlos Cruz-Montecinos
Carlos Cruz-Montecinos
JCJuan José Carrasco
Juan José Carrasco
BGBenjamín Guzmán-González
Benjamín Guzmán-González
VSVerónica Soto‐Arellano
Verónica Soto‐Arellano
Joaquín CalatayudJoaquín Calatayud
Joaquín Calatayud
SPSofía Pérez-Alenda
Sofía Pérez-Alenda

1 August 2019 in Applied Physiology, Nutrition, and Metabolism
Verified
Journal Article
Closed access
BGBenjamín Guzmán-González
Benjamín Guzmán-González
PLPablo Llanos
Pablo Llanos
JCJoaquín Calatayud
Joaquín Calatayud
NMNicola A. Maffiuletti
Nicola A. Maffiuletti
Carlos Cruz-MontecinosCarlos Cruz-Montecinos
Carlos Cruz-Montecinos
Consensus is lacking regarding optimal neuromuscular electrical stimulation (NMES) parameters for postprandial glycemic control. Therefore, the aim of this study was to determine the NMES frequency inducing the greatest hypoglycemic effect in healthy individuals. The secondary aim was to compare current-related discomfort and muscle soreness between different frequencies. We conducted an experimental clinical study with a randomized crossover design. Sixteen healthy and sedentary participants received NMES for 20 min at 5, 10, or 50 Hz (pulse duration: 400 μs, on-off ratio: 4:12 s) following a standardized meal. Glycemia, discomfort, and muscle soreness during and after NMES were compared between conditions. Five-hertz NMES generated a significant hypoglycemic effect, contrary to 10 Hz and 50 Hz. Ten-hertz and 50-Hz NMES resulted respectively in lower current-related discomfort and greater muscle soreness compared with the other frequencies. Women reported higher discomfort than men. These findings contribute towards the possibility of more efficient long-term NMES treatments in terms of glycemic response and patient tolerance.